The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
The medical-grade Angelas diode laser calibrated at a 1470 nm wavelength supports microsurgeries across multiple specialties
Offers a non-surgical treatment option for tricuspid regurgitation, a commonly underdiagnosed heart valve disorder linked to heart failure
The event showcased latest breakthroughs in minimally invasive surgery, organ-preservation strategies, and targeted therapies
The combination also outperformed chemotherapy on another important secondary endpoint
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
Adding one year of Imfinzi treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone
Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
